544009

- Blue Jet Healthcare Limited submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. - The report highlights an increase in renewable energy consumption from 26,321.38 GJ (FY24-25) to 40,836.79 GJ (FY25-26). - Scope 1 and Scope 2 GHG emissions were reduced from 34,885.47 tCO2 (FY24-25) to 32,138.47 tCO2 (FY25-26). - The company implemented a Zero Liquid Discharge (ZLD)-based water management system and recycled 48,827 KL of water in FY25-26.

- Q1 FY27 saw revenue from operations of INR293 crores (▲25% sequentially) and operating EBITDA of INR98 crores (▲3% sequentially to 33.5% margin), reflecting healthy sequential improvement. - Gross margin reduced by 3% sequentially to 53% and PAT marginally declined QoQ, primarily due to increased raw material prices and product mix, as well as lower other income. - INR30 crores of Contrast Media sales were delayed due to transit issues and are expected to be recognized in Q2. - Hyderabad R&D center is expected to be operational this month, and the Unit 3 backward integration project for contrast media intermediates is ahead of schedule, expected to contribute commercially in H2 FY27. - The Vizag project, with an investment of approximately INR1,000 crores over three years, has commenced to expand manufacturing and innovation capabilities across GMP intermediates, complex APIs, and CDMO. - Management expects to launch 3 new Contrast Media candidates and initiate pilot activities for a new high-intensity sweetener in FY27, with strong visibility for the PI API segment over the next 3-4 quarters. - The company focuses on platform diversification into new areas like peptide fragments and GLP-1 intermediates, pursuing a selective CDMO model. - Long-term capital expenditure is guided at approximately INR1,000 crores over the next three years, with INR250 crores expected in FY27.

- Submission of audio recording of the earnings conference call held to discuss financial results for the quarter ended June 30, 2026. - The recording is available on the company's website: https://bluejethealthcare.com/investor-presentation/

- Standalone Revenue ₹2,931.13Mn vs ₹3,547.58Mn (▼17.37% YoY) - EBITDA ₹1,133.12Mn vs ₹1,292.48Mn (▼12.33% YoY) - PAT ₹782.64Mn vs ₹911.70Mn (▼14.16% YoY) - EBITDA Margin 38.66% vs 36.43% (▲223bps) - Board approved re-appointment of Mr. Akshay B Arora as Whole Time Director & Executive Chairman for 5 years. - Board approved re-appointment of Mr. Shiven Akshay Arora as Managing Director for 5 years. - Board approved re-appointment of M/s KKC & Associates LLP as Statutory Auditors for a second term of 5 years. - Board declared a dividend of ₹1.2/- per equity share (@60%) for FY 2025-26. - 58th Annual General Meeting (AGM) to be held on September 21, 2026.

- Standalone Revenue ₹293.11 Cr vs ₹354.76 Cr (▲-17.4% YoY) - Standalone EBITDA ₹98.08 Cr vs ₹120.99 Cr (▲-18.9% YoY) - Standalone PAT ₹78.26 Cr vs ₹91.17 Cr (▲-14.2% YoY) - Standalone EBITDA Margin 33.46% vs 34.11% (▼65 bps) - Board declared a dividend of ₹1.2/- per Equity Share (60% on face value of ₹2/-) for FY 2025-26, with record date September 14, 2026. - Re-appointment of Mr. Akshay B Arora as Whole Time Director & Executive Chairman for five years. - Re-appointment of Mr. Shiven Akshay Arora as Managing Director for five years. - Re-appointment of M/s KKC & Associates LLP as Statutory Auditors for a second term of five years. - 58th Annual General Meeting (AGM) to be held on September 21, 2026.

- Standalone Revenue ₹2,931.13 Mn vs ₹3,547.58 Mn (▼17.4% YoY) - EBITDA ₹980.75 Mn vs ₹1,209.94 Mn (▼18.8% YoY) - PAT ₹782.64 Mn vs ₹911.70 Mn (▼14.2% YoY) - EBITDA Margin 33.46% vs 34.11% (▼65 bps)

- Standalone Revenue ₹293.11Cr vs ₹354.76Cr (▼17.38% YoY) - EBITDA ₹98.08Cr vs ₹121.00Cr (▼18.94% YoY) - PAT ₹78.26Cr vs ₹91.17Cr (▼14.15% YoY) - EBITDA Margin 33.46% vs 34.11% (▼65bps) - Board recommended a dividend of ₹1.2/- per equity share for FY 2025-26. - Re-appointment of Mr. Akshay B Arora as Whole Time Director and Executive Chairman for 5 years. - Re-appointment of Mr. Shiven Akshay Arora as Managing Director for 5 years. - Re-appointment of M/s KKC & Associates LLP as Statutory Auditors for 5 years. - The 58th Annual General Meeting (AGM) will be held on September 21, 2026.

- Standalone Operating Revenue ₹293.11Cr vs ₹354.76Cr (▼17.4% YoY) - EBITDA ₹98.08Cr vs ₹120.99Cr (▼18.9% YoY) - PAT ₹78.26Cr vs ₹91.17Cr (▼14.1% YoY) - EBITDA Margin 33.46% vs 34.11% (▼65bps)

- Concall Schedule - Concall Date: Monday, August 03, 2026 - Concall Time: 5:30 PM IST - To discuss Unaudited Standalone Financial Results for the quarter ended June 30, 2026.

- Board meeting scheduled for August 03, 2026. - To approve Unaudited Standalone Financial Results for the quarter ended June 30, 2026. - Trading window to remain closed until August 06, 2026.

- Blue Jet Healthcare Limited received the EcoVadis Silver Medal for outstanding sustainability management practices, effective July 20, 2026. - The company ranks among the top 15% globally with a 90th percentile ranking in sustainability performance. - Achieved an EcoVadis Sustainability Score of 77 out of 100.

New Filing detected. See link for details.

New Filing detected. See link for details.

- Blue Jet Healthcare Limited announced the Qualified Institutions Placement (QIP) of equity shares. - The Investment and Finance Committee, on July 6, 2026, approved the preliminary placement document and set the floor price at ₹531.70 per Equity Share. - The QIP issue opened on July 6, 2026, with a potential discount of up to 5% on the floor price.

- Submission of Audited Standalone Financial Statements for the Financial Year ended March 31, 2026, approved by the Board on May 25, 2026. - Auditors (KKC & Associates LLP) noted disputed income tax liabilities totaling approx. ₹1768.86 million (net of deposits) for AY 2020-21 to 2023-24. - Internal control weaknesses were identified regarding audit trails: inventory records were manual in spreadsheets without audit trail up to December 7, 2025, and the auditor was unable to comment on the audit trail for third-party payroll software. - Title deeds for certain immovable properties (leasehold land and building) are still in the process of being transferred to the company after amalgamation/merger.

- Submitted Audited Standalone Financial Statements for FY26 with an unqualified audit opinion. - Board proposed final dividend for FY26. - Auditors noted manual inventory records, pending property title transfers, and significant disputed income tax dues for various assessment years.

- Trading window closed for Designated Persons and their immediate relatives as per SEBI (Prohibition of Insider Trading) Regulations, 2015. - Effective from July 1, 2026, until 48 hours after the declaration of Unaudited Standalone Financial Results for the first quarter ended June 30, 2026.

- Blue Jet Healthcare Limited announced the voting results of its EGM held on June 17, 2026. - A special resolution to approve raising of funds via issuance of Equity Shares and/or other Eligible Securities was passed with 99.9999% votes in favor.

- An Extra-Ordinary General Meeting (EGM) of Blue Jet Healthcare Limited was held on June 17, 2026, at 11:00 AM via Video Conferencing/OAVM. - The key agenda item was to consider and approve raising of funds by issuance of Equity Shares and/or other Eligible Securities through a special resolution. - E-voting facilities were provided, and the results of the voting will be declared within the stipulated time. - The meeting concluded at 11:29 AM IST.

- Blue Jet Healthcare Limited responded to an email from BSE/NSE dated June 12, 2026, regarding significant volume movement in its shares. - The company stated all necessary disclosures were made, and volume movement is due to market conditions.

New Filing detected. See link for details.

Blue Jet Healthcare described FY26 as a foundational year with significant investments, despite a decline in overall revenue and muted EBITDA primarily due to PI/API destocking. For FY27, management guided for double-digit growth in the contrast media segment, driven by 3-4 new product launches and backward integration. The PI segment is expected to recover and exceed FY25 peak levels as inventory destocking normalizes. The company plans a capex of approximately INR 1,000 crores over 3 years for the Vizag greenfield project and INR 40 crores for a new Hyderabad R&D center, targeting peptide-related intermediates and GLP-1 opportunities. Blue Jet Healthcare remains debt-free with strong liquidity, expecting improved business visibility and commercialization of new products in FY27.

Blue Jet Healthcare Limited has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report, issued by Mehta and Mehta, Company Secretaries, confirms the company's full compliance with all applicable SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other relevant SEBI regulations and secretarial standards. No non-compliances, regulatory actions, or auditor resignations were observed during the review period.